Sesen Bio — Corporate Update (March 2019)
36 slides from Sesen Bio's corporate update, Mar 4, 2019
Slide 1: Business Update March 4, 2019
Business Update March 4, 2019 NASDAQ SESN
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and our ability to successfully develop our product candidates and complete our planned uncertainties. All statements, other than statements of historical facts, contained in this clinical
Slide 3: Agenda
AGENDA 1. Bladder cancer is an area of significant unmet need, which results in strong stakeholder support for new treatment options 2. Confident in the probability of regulatory approval with a clear path forward 3. Dual MOA suggests that Vicinium® may be a preferred choice for combination therapy
Slide 4: Our Path Forward Starts with the Patient Journey
BLOOD IN URINE See PCP; prescribed OUR PATH FORWARD STARTS misaligned antibiotics WITH THE PATIENT JOURNEY Still see blood in urine See blood in urine; Patient surveys have shown that the experience of those Confusion and concern on problem try different antibiotic with bladder cancer is one of the
Slide 5: Bladder Cancer: Tremendous Unmet Medical Need
BLADDER CANCER Highly Prevalent with th MOST COMMON 6 CANCER1 Tremendous Unmet Medical Need • Median age at diagnosis of 72 years1 • Single most expensive cancer to treat in U.S.2 >80,000 - Average patient cost is ~$150K3 NEW CASES EACH YEAR IN U.S.1 • 75-85% diagnosed as non-muscle invasive bladder
Slide 6: Carcinoma in situ: the most difficult form of NMIBC to treat
Carcinoma in situ: the most difficult form of NMIBC to treat Carcinoma in situ vs. Normal Bladder Lining: Clinical Trial Implications: • Field change disease often involving the entire bladder lining that is very difficult to treat • Failed on two courses of BCG, which is the gold standard for treat
Slide 7: Agenda
AGENDA 1. Bladder cancer is an area of significant unmet need, which results in strong stakeholder support for new treatment options 2. Confident in the probability of regulatory approval with a clear path forward 3. Dual MOA suggests that Vicinium may be a preferred choice for combination therapy w
Slide 8: Vicinium
VICINIUM • Antibody fragment targeting EpCAM tethered to a cytotoxic payload (Pseudomonas exotoxin A) to form a single protein • Highly selective targeting of cancer cells while mostly avoiding healthy cells • Inhibits protein synthesis, and kills both rapidly proliferating and slow- growing cells •
Slide 9: Vicinium Clinical Program Highly Aligned with 2018 FDA Guidance for NMIBC
VICINIUM Clinical Program Highly Aligned with 2018 FDA Guidance for NMIBC FDA Guidance VICINIUM Clinical Program • Conduct nonclinical studies to assess toxicity in animal models • Conduct nonclinical studies to demonstrate anti-tumor activity • Conduct nonclinical studies to determine optimal d
Slide 10: Spectrum of Clinical Trial Endpoints in VISTA Demonstrating Strong Benefit/Risk Profile
Spectrum of Clinical Trial Endpoints in VISTA Demonstrating Strong Benefit/Risk Profile Efficacy Surrogate Time to Health Endpoints Cystectomy Outcomes Benefit : Risk Safety and Tolerability Favorable profile relative to BCG, Valstar, checkpoint inhibitors Selectively targets cancer cells while gene
Slide 11: Phase II and Phase III Trials Highly Consistent for Complete Response Rate
Our Phase II and Phase III Clinical Trials are Highly Consistent for Complete Response Rate (CRR) CRR in Carcinoma in situ Patients* 50% Legend: Phase II 40% Phase III 40% 39% 95% CI 30% 27% 27% 20% 20% 18% 16% 10% 14% % of Patients with Complete Complete Response with Patients % of 0% 3-Month3-mont
Slide 12: VISTA Trial: Duration of Response for Patients with CR at 3 Months
VISTA TRIAL: Duration of Response for Patients who Achieved a CR at 3 Months CIS Patients (cohorts 1 & 2) (n=93) Patients with Complete Patients Patients still on treatment in situ Response at 3 months 49% of patients had a CR duration of ≥9 months (or 12 months after starting therapy) Carcinoma Car
Slide 13: VISTA Trial: Favorable Efficacy in High-risk Ta or T1 NMIBC Patients
VISTA TRIAL: Favorable Efficacy Demonstrated in High-risk Ta or T1 NMIBC Patients Recurrence-Free Rate 80% 70% • Patients deemed to have no visible 60% 68% evidence of disease when starting Free Vicinium treatment - 50% 56% • Disease recurrence remains 40% appropriate response criteria 42% 30% 36% •
Slide 14: VISTA Trial: High-Risk Ta or T1 Patients Remain Disease Free for ~9 Months
VISTA TRIAL: After Treatment with Vicinium, Patients with High-Risk Ta or T1 NMIBC Remain Disease Free for ~9 Months Vicinium High-risk Ta or T1 Patients (cohort 3, n=40) Patients still on treatment Median time to disease recurrence = 270* (95% CI = 169-452) grade Ta, T1 NMIBC Patients treated with
Slide 15: VISTA Trial: Patients Projected Cystectomy-Free for ~18 Months
VISTA TRIAL: After Treatment with Vicinium, Patients are Projected to be Cystectomy-Free for ~18 Months CIS Patients (cohorts Vicinium 1&2, n=93) High-risk Ta or T1 Patients (cohort 3, n=40) Patient still on trial, no cystectomy as of last visit Patients treated treated with Patients Median cystecto
Slide 16: Phase II and Phase III Trials Highly Consistent for Safety and Tolerability
Our Phase II and Phase III Clinical Trials are Highly Consistent for Safety and Tolerability No patient developed metastatic bladder cancer while on therapy in Phase II or Phase III trials • Majority of adverse events considered Phase II Phase III mild/moderate in both studies Category (n=46) (n=133
Slide 17: Agenda
AGENDA 1. Bladder cancer is an area of significant unmet need, which results in strong stakeholder support for new treatment options 2. Confident in the probability of regulatory approval with a clear path forward 3. Dual MOA suggests that Vicinium may be a preferred choice for combination therapy w
Slide 18: Vicinium Dual Mechanism of Action
VICINIUM Dual Mechanism of Action Fusion Protein: Vicinium selectively targets cancer cells (which overexpress T-cell recognizes EpCAM) neoantigen and kills cancer cell MECHANISM 2: Scientific Hypothesis: Vicinium may have an additive or synergistic effect with checkpoint inhibitors enabled by Vicin
Slide 19: Testing the Scientific Hypothesis: Pre-clinical and Phase I Trial in SCCHN
Testing the Scientific Hypothesis: Pre-clinical and Phase I Trial in SCCHN shows evidence of activation of patients’ immune systems Pre-Clinical Evidence Clinical Evidence (as seen in Phase I) After 4wks on Pre- treatment . Immunogenic Cell Death (ICD) treatment • Promotes a pro-inflammatory environ
Slide 20: Testing the Scientific Hypothesis: NCI Trial of Vicinium and Checkpoint Inhibitor
Testing the Scientific Hypothesis: NCI Trial of Vicinium and Checkpoint Inhibitor TRIAL ASSESSING: • Expression of ligands (e.g., PD-L1 and PD-L2) and DATA EXPECTED TO interaction with checkpoints (e.g., PD-1 and CD-80) GUIDE ADDITIONAL • Biomarkers • Complete response rate and duration of response
Slide 21: Agenda
AGENDA 1. Bladder cancer is an area of significant unmet need, which results in strong stakeholder support for new treatment options 2. Confident in the probability of regulatory approval with a clear path forward 3. Dual MOA suggests that Vicinium may be a preferred choice for combination therapy w
Slide 22: Physician and Key Opinion Leader Commercial Insights Based on New Clinical Data
Physician and Key Opinion Leader Commercial Insights Based on New Clinical Data(6 High- Prescribing Urologists and 5 KOLs) After reviewing the data, these high- After reviewing the data, these prescribing Urologists state they would KOLs would recommend prescribe Vicinium to Vicinium to Would Would
Slide 23: Addressable Market (US Only)
Addressable Market (US Only) Annual Volume Price Reference (Annual Cost) ~80K1 $200K Patients diagnosed with bladder cancer 75% - 85% of Average Checkpoint bladder cancer healthcare cost diagnoses are Inhibitors6 NMBIC2 per patient Patients diagnosed with NMIBC with bladder 40% - 50% of cancer7 NMBI
Slide 24: Vicinium has Potential to Provide Continuity of Care for Patients with NMIBC
VICINIUM has Potential to Provide Continuity of Care for Patients with NMIBC VICINIUM BCG TREATMENT TREATMENT 2-hour infusion, hold, and rotation “I have been struck by the high patient tolerability of Vicinium which is instilled just Administration through urinary catheter like intravesical chemoth
Slide 25: Vicinium Go-to-Market Strategy Focuses on Key Customer Segments
Vicinium Go-to-Market Strategy Focuses on 3 Key Customer Segments Customer Segment Key Leverage Points Desired Behavior Clinical trial data Prescribing Vicinium Physician Clinical experience before cystectomy Patient Quality of Life Ask doctor for (Families/Caregivers) Health Outcomes Vicinium Payer
Slide 26: Agenda
AGENDA 1. Bladder cancer is an area of significant unmet need, which results in strong stakeholder support for new treatment options 2. Confident in the probability of regulatory approval with a clear path forward 3. Dual MOA suggests that Vicinium may be a preferred choice for combination therapy w
Slide 27: Vicinium: A Single cGMP Manufacturing Process
Vicinium: A single cGMP Manufacturing Process Vicinium: simple (linear) cGMP manufacturing process producing a single fusion protein QA QA Purification Release Fill/Finish Release Bioreactor (Generates Drug (Generates Drug Market Substance) Product) Single cGMP process ADCs: complex (branched) cGMP
Slide 28: 2019 Outlook
2019 Outlook December 31, 2018 December 31, 2017 Cash and Cash $50.4M $14.7M Equivalents Outstanding Shares 77,456,180 34,702,565 . Cash and cash equivalents sufficient to fund operations into 2020, with no outstanding debt . Potential value inflection points by mid-2019: • Ongoing FDA interaction a
Slide 29: 2019 Company Highlights
2019 COMPANY HIGHLIGHTS 1. Bladder cancer is an area of significant unmet need, which results in strong stakeholder support for new treatment options 2. Confident in the probability of regulatory approval with a clear path forward 3. Dual MOA suggests that Vicinium may be a preferred choice for comb
Slide 30: Appendix
Appendix *s sesen 30
Slide 31: VISTA Trial: Patient Demographics
VISTA TRIAL: PATIENT DEMOGRAPHICS COHORT 1 COHORT 2 COHORT 3 Papillary tumors (without CHARACTERISTICS CIS that recurred >6 CIS that recurred within 6 CIS) that recurred within months but ≤11 months of months of adequate BCG 6 months of adequate adequate BCG BCG Total patients enrolled 86 7 40 Evalu
Slide 32: Vicinium Patent Life
VICINIUM® PATENT LIFE Pending Applications Dosing Strategies for Targeting EPCAM positive bladder cancer. If allowed, Stablilized Chimeric Immunoglobulins would expire in 2036 or later. (Oct 2021- Jan 2022) US: 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036
Slide 33: VISTA Trial: Data Tables, Complete Response Rate
VISTA TRIAL: Data Tables, Complete Response Rate Cohort 1 (n=86) Time Point Evaluable Patients Complete Response Rate (95% Confidence Interval) 3-months n=86 37% (27%-48%) 6-months n=85 25% (16%-35%) 9-months n=84 18% (10%-28%) 12-months n=81 14% (7%-23%) Cohort 2 (n=7) Time Point Evaluable Patients
Slide 34: VISTA Trial: Data Tables, Complete Response Rate, Pooled Cohorts 1 & 2
VISTA TRIAL: Data Tables, Complete Response Rate Pooled cohorts 1 & 2 (n=93) Time Point Evaluable Patients Complete Response Rate (95% Confidence Interval) 3-months n=93 39% (29%-49%) 6-months n=92 27% (18%-37%) 9-months n=91 20% (12%-29%) 12-months n=88 14% (7%-23%) 34
Slide 35: VISTA Trial: Data Tables, Preliminary Phase III CRR vs. Phase II CRR
VISTA TRIAL: Data Tables, Complete Response Rate Preliminary Phase III CRR vs. Phase II CRR Time Point Phase 3 Pooled CRR (95% Confidence Interval) Phase 2 Pooled CRR (95% Confidence Interval) 3-months 39% (29%, 49%) 40% (26%-56%) 6-months 27% (18%, 37%) 27% (15%-42%) 9-months 20% (12%, 29%) 18% (8%
Slide 36: VISTA Trial: Data Tables, Disease Recurrence
VISTA TRIAL: Data Tables, Disease Recurrence Cohort 3 (n=40) Recurrence-Free Rate (95% Confidence Time Point Evaluable Patients Interval) 3-months n=40 68% (51%-81%) 6-months n=40 56% (40%-72%) 9-months n=39 42% (26%-59%) 12-months n=38 36% (21%-54%) 36